– USA, WY – SynAgile Corporation, a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse technology platform, today announced the closing of a convertible debt investment of >$9 million. The proceeds will be used to complete the Phase 2 clinical trial of the DopaFuse delivery system and initiate manufacturing scale-up in preparation for its Phase III trial. The Phase II trial is currently underway in Luxembourg, Italy, and Spain. The DopaFuse delivery system is the first non-invasive, continuous, levodopa-carbidopa delivery system. DopaFuse has the potential to treat motor fluctuations and dyskinesia associated with Parkinson’s disease.
Concurrent with the financing, Michael McNamara has joined the Board of Directors.
About Michael McNamara
Mr. McNamara spent 12 years as CEO of Flex, one of the world’s largest multinational technology manufacturing companies, where he grew the company to $25B in revenue and over 200,000 employees operating in 30+ countries. Mr. McNamara serves on the Board of Directors of Carrier, Workday, and PCH International, and was previously on boards of many other companies including Slack Technologies, Delphi, SunEdison, and Therasense. He is also a venture partner at Eclipse Ventures.
SynAgile is a pharmaceutical company focused on developing and commercializing therapeutics using its proprietary OraFuse noninvasive, continuous, oral dosing technology, with an initial focus on treating debilitating motor complications in patients with Parkinson’s disease using its DopaFuse levodopa-carbidopa delivery system.
For more information: http://www.synagile.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.